TLDR Alibaba’s U.S. stock surged 12.9% to $135 after Q2 FY25 results on August 29 Hong Kong-listed shares soared 19% to their highest level since March Cloud revenue rose 26% to 33.4 billion yuan, beating expectations Alibaba is developing a new AI chip, fueling further investor confidence Quick commerce expansion drags profits but investors focus [...] The post Alibaba Group Holding Limited ($BABA) Stock: AI and Cloud Growth Ignite 19% Rally Despite Quick Commerce Drag appeared first on CoinCentral.TLDR Alibaba’s U.S. stock surged 12.9% to $135 after Q2 FY25 results on August 29 Hong Kong-listed shares soared 19% to their highest level since March Cloud revenue rose 26% to 33.4 billion yuan, beating expectations Alibaba is developing a new AI chip, fueling further investor confidence Quick commerce expansion drags profits but investors focus [...] The post Alibaba Group Holding Limited ($BABA) Stock: AI and Cloud Growth Ignite 19% Rally Despite Quick Commerce Drag appeared first on CoinCentral.

Alibaba Group Holding Limited ($BABA) Stock: AI and Cloud Growth Ignite 19% Rally Despite Quick Commerce Drag

TLDR

  • Alibaba’s U.S. stock surged 12.9% to $135 after Q2 FY25 results on August 29
  • Hong Kong-listed shares soared 19% to their highest level since March
  • Cloud revenue rose 26% to 33.4 billion yuan, beating expectations
  • Alibaba is developing a new AI chip, fueling further investor confidence
  • Quick commerce expansion drags profits but investors focus on long-term AI

Alibaba Group Holding Limited (NYSE: BABA) closed at $135.00 on August 29, up 12.90%, as investors cheered accelerating growth in its cloud division and optimism around artificial intelligence.

Alibaba Group Holding Limited (BABA)

The rally marked the stock’s best close in months and came after Alibaba’s Q2 FY25 results highlighted both progress and challenges.

Cloud Unit Shines with 26% Growth

For the quarter ended June 30, Alibaba reported revenue of 247.65 billion yuan ($34.73 billion), a modest 2% year-over-year rise that fell short of analyst forecasts. Still, the bright spot was Alibaba Cloud, which posted a 26% annual revenue surge to 33.4 billion yuan, far outpacing expectations of 18% growth.

The company noted that AI-related product revenue grew triple digits for the eighth straight quarter, signaling strong momentum as enterprises adopt Alibaba’s infrastructure for inference and training workloads. CEO Eddie Wu said investments in AI are “yielding tangible results,” with analysts at Jefferies calling cloud “the long-term growth engine.”

AI Chip Development Boosts Sentiment

On top of the cloud results, CNBC reported that Alibaba is developing a new AI chip, a move that could strengthen its competitive edge against global tech giants. The news fueled Monday’s rally in Hong Kong, where Alibaba’s shares jumped 19%, reaching their highest since March.

Core E-Commerce Growth and Instant Commerce Costs

Alibaba’s core China commerce division generated 140 billion yuan in revenue, up 10% year-over-year. Yet profitability took a hit as EBITA fell 21%, driven by subsidies in the company’s aggressive push into “instant commerce” — one-hour deliveries through its Taobao app.

The instant commerce market pits Alibaba against rivals Meituan and JD.com, both locked in heavy spending battles. Jiang Fan, head of e-commerce, admitted losses are steep but argued repeat customers will drive efficiency. Analysts at Nomura and Morningstar suggested Alibaba is better positioned than in past food delivery battles, with its ecosystem integration offering competitive advantages.

Investor Perspective: AI Over Food Delivery Losses

While quick commerce remains a drag, investors are clearly prioritizing Alibaba’s AI and cloud trajectory. Net income surged 78% year-over-year, offsetting the revenue miss and supporting the stock rally. Analysts believe the cloud division could follow a path similar to Microsoft Azure and Google Cloud in monetizing AI services.

Performance Overview: BABA vs. Hang Seng

Despite the five-year decline, Alibaba’s stock has been a standout performer in 2025:

  • YTD Return: +63.18% vs Hang Seng’s +27.70%
  • 1-Year Return: +64.72% vs Hang Seng’s +42.41%
  • 3-Year Return: +48.99% vs Hang Seng’s +30.72%
  • 5-Year Return: -50.48% vs Hang Seng’s +1.72%

The long-term chart reflects Alibaba’s volatile journey, but investors now see a clearer growth path centered on AI, cloud acceleration, and ecosystem strength, with near-term profitability taking a back seat.

 

The post Alibaba Group Holding Limited ($BABA) Stock: AI and Cloud Growth Ignite 19% Rally Despite Quick Commerce Drag appeared first on CoinCentral.

Market Opportunity
Cloud Logo
Cloud Price(CLOUD)
$0.06959
$0.06959$0.06959
+0.43%
USD
Cloud (CLOUD) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Over $145M Evaporates In Brutal Long Squeeze

Over $145M Evaporates In Brutal Long Squeeze

The post Over $145M Evaporates In Brutal Long Squeeze appeared on BitcoinEthereumNews.com. Crypto Futures Liquidations: Over $145M Evaporates In Brutal Long Squeeze
Share
BitcoinEthereumNews2026/01/16 11:35
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Edges higher ahead of BoC-Fed policy outcome

Edges higher ahead of BoC-Fed policy outcome

The post Edges higher ahead of BoC-Fed policy outcome appeared on BitcoinEthereumNews.com. USD/CAD gains marginally to near 1.3760 ahead of monetary policy announcements by the Fed and the BoC. Both the Fed and the BoC are expected to lower interest rates. USD/CAD forms a Head and Shoulder chart pattern. The USD/CAD pair ticks up to near 1.3760 during the late European session on Wednesday. The Loonie pair gains marginally ahead of monetary policy outcomes by the Bank of Canada (BoC) and the Federal Reserve (Fed) during New York trading hours. Both the BoC and the Fed are expected to cut interest rates amid mounting labor market conditions in their respective economies. Inflationary pressures in the Canadian economy have cooled down, emerging as another reason behind the BoC’s dovish expectations. However, the Fed is expected to start the monetary-easing campaign despite the United States (US) inflation remaining higher. Investors will closely monitor press conferences from both Fed Chair Jerome Powell and BoC Governor Tiff Macklem to get cues about whether there will be more interest rate cuts in the remainder of the year. According to analysts from Barclays, the Fed’s latest median projections for interest rates are likely to call for three interest rate cuts by 2025. Ahead of the Fed’s monetary policy, the US Dollar Index (DXY), which tracks the Greenback’s value against six major currencies, holds onto Tuesday’s losses near 96.60. USD/CAD forms a Head and Shoulder chart pattern, which indicates a bearish reversal. The neckline of the above-mentioned chart pattern is plotted near 1.3715. The near-term trend of the pair remains bearish as it stays below the 20-day Exponential Moving Average (EMA), which trades around 1.3800. The 14-day Relative Strength Index (RSI) slides to near 40.00. A fresh bearish momentum would emerge if the RSI falls below that level. Going forward, the asset could slide towards the round level of…
Share
BitcoinEthereumNews2025/09/18 01:23